Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 1
2000 1
2008 2
2009 1
2011 1
2012 1
2014 2
2015 1
2018 1
2019 1
2020 2
2021 3
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Among authors: drullinsky p. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Clinical Trial.
The median progression-free survival was 3.2 months (95% CI 2.0-4.5) for patients in the standard-of-care group versus 7.2 months (4.5-10.0) for patients in the SBRT group (hazard ratio [HR] 0.53, 95% CI 0.35-0.81; p=0.0035). The median progression-free survival was higher …
The median progression-free survival was 3.2 months (95% CI 2.0-4.5) for patients in the standard-of-care group versus 7.2 months (4.5-10.0) …
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, Matasar MJ, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A. Epstein-Peterson ZD, et al. Among authors: drullinsky p. Haematologica. 2024 Apr 1;109(4):1149-1162. doi: 10.3324/haematol.2023.282898. Haematologica. 2024. PMID: 37646671 Free PMC article. Clinical Trial.
By intent-to-treat, rates of overall and complete response were equivalent at 88% (43/49), one patient with stable disease, and two patients had disease progression during study; 3-year progression-free survival was 63% (primary endpoint not met) and differed by TP53 status (78% …
By intent-to-treat, rates of overall and complete response were equivalent at 88% (43/49), one patient with stable disease, and two patients …
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ. Borchmann S, et al. Among authors: drullinsky p. Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15. Blood. 2019. PMID: 30770396 Free PMC article.
Patients managed with active surveillance had slightly shorter PFS than those receiving any active treatment, with 5-year PFS of 77% (95% CI, 56-89) vs 87% (95% CI, 79-92; P = .017). This difference did not translate into better PFS2 or OS. ...
Patients managed with active surveillance had slightly shorter PFS than those receiving any active treatment, with 5-year PFS of 77% (95% CI …
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
Schwartz CJ, da Silva EM, Marra A, Gazzo AM, Selenica P, Rai VK, Mandelker D, Pareja F, Misyura M, D'Alfonso TM, Brogi E, Drullinsky P, Razavi P, Robson ME, Drago JZ, Wen HY, Zhang L, Weigelt B, Shia J, Reis-Filho JS, Zhang H. Schwartz CJ, et al. Among authors: drullinsky p. Clin Cancer Res. 2022 Jan 15;28(2):404-413. doi: 10.1158/1078-0432.CCR-21-2027. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667028 Free PMC article.
Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
Epstein-Peterson ZD, Ganesan N, Barker JN, Drullinsky PR, Ghione P, Jakubowski AA, Kumar A, Moskowitz AJ, Noy A, Perales MA, Ponce DM, Schoder H, Young JW, Giralt SA, Horwitz SM, Sauter CS, Dahi PB. Epstein-Peterson ZD, et al. Among authors: drullinsky pr. Leuk Lymphoma. 2021 Sep;62(9):2177-2183. doi: 10.1080/10428194.2021.1897806. Epub 2021 Mar 29. Leuk Lymphoma. 2021. PMID: 33779474 Free PMC article.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S, Cortés J, Im YH, Diéras V, Harbeck N, Krop IE, Wilson TR, Cui N, Schimmoller F, Hsu JY, He J, De Laurentiis M, Sousa S, Drullinsky P, Jacot W. Dent S, et al. Among authors: drullinsky p. Ann Oncol. 2021 Feb;32(2):197-207. doi: 10.1016/j.annonc.2020.10.596. Epub 2020 Nov 10. Ann Oncol. 2021. PMID: 33186740 Free PMC article. Clinical Trial.
INV-PFS was significantly improved in the taselisib {7.4 months [95% confidence interval (CI), 7.26-9.07]} versus placebo arm (5.4 months [95% CI, 3.68-7.29]) (stratified hazard ratio [HR] 0.70; 95% CI, 0.56-0.89; P = 0.0037) and confirmed by BICR-PFS (HR 0.66). Secondary …
INV-PFS was significantly improved in the taselisib {7.4 months [95% confidence interval (CI), 7.26-9.07]} versus placebo arm (5.4 months [9 …
Extent, risk factors, and outcome of fluid overload after pediatric heart surgery*.
Seguin J, Albright B, Vertullo L, Lai P, Dancea A, Bernier PL, Tchervenkov CI, Calaritis C, Drullinsky D, Gottesman R, Zappitelli M. Seguin J, et al. Among authors: drullinsky d. Crit Care Med. 2014 Dec;42(12):2591-9. doi: 10.1097/CCM.0000000000000517. Crit Care Med. 2014. PMID: 25072753
Fluid overload peaked on PICU day 2. Lack of past cardiac surgery (p = 0.04), cyanotic heart disease (p = 0.03), and early postoperative fluids (p = 0.0001) was independently associated with higher day 2 fluid overload %. Day 2 fluid overload % predicted long …
Fluid overload peaked on PICU day 2. Lack of past cardiac surgery (p = 0.04), cyanotic heart disease (p = 0.03), and early pos …
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH. Sauter CS, et al. Among authors: drullinsky p. Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31. Blood. 2018. PMID: 29386196 Free PMC article. Clinical Trial.
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. Dang C, et al. Among authors: drullinsky p. J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733. J Clin Oncol. 2008. PMID: 18323546 Clinical Trial.
PURPOSE: Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) is superior to every 3-weekly AC followed by P. Given the demonstrated cardiac safety for trastuzumab (T) with conventionally scheduled AC followed by P, we tested the s …
PURPOSE: Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (P) is superior to every 3-weekly AC followed b …
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA, Jhaveri KL, Lake DE, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Wang DG, et al. Among authors: drullinsky pr. Breast Cancer Res Treat. 2020 Aug;183(1):227-237. doi: 10.1007/s10549-020-05726-y. Epub 2020 Jun 29. Breast Cancer Res Treat. 2020. PMID: 32613539 Free PMC article.
All-grade rash correlated with an increase in serum eosinophils from 2.7 to 4.4%, p < 0.05, and prophylaxis with non-sedating antihistamines (n = 43) was correlated with a reduction of grade 1/2 rash (OR 0.39, p = 0.09). ...

All-grade rash correlated with an increase in serum eosinophils from 2.7 to 4.4%, p < 0.05, and prophylaxis with non-sedating anti

…
17 results